Ionis Pharmaceuticals Inc
IONS86.500USD
+3.020+3.62%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
13.94BCap. mercado
PérdidaP/E TTM
Más Datos de Ionis Pharmaceuticals Inc Compañía
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Información de Ionis Pharmaceuticals Inc
Símbolo de cotizaciónIONS
Nombre de la empresaIonis Pharmaceuticals Inc
Fecha de salida a bolsaMay 17, 1991
Director ejecutivoMonia (Brett P)
Número de empleados1069
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 17
Dirección2855 Gazelle Court
CiudadCARLSBAD
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92010
Teléfono17609319200
Sitio Webhttps://www.ionis.com/
Símbolo de cotizaciónIONS
Fecha de salida a bolsaMay 17, 1991
Director ejecutivoMonia (Brett P)
Ejecutivos de Ionis Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
283.93K
+104355.00%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+4079.00%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
132.88K
+22381.00%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
71.98K
+18094.00%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
66.25K
+17421.00%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
65.67K
+18195.00%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
59.66K
--
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
47.87K
+17294.00%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
36.33K
--
Ms. Shannon L. Devers
Ms. Shannon L. Devers
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
22.54K
+5047.00%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
283.93K
+104355.00%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+4079.00%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
132.88K
+22381.00%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
71.98K
+18094.00%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
66.25K
+17421.00%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
65.67K
+18195.00%
Desglose de ingresos
Divisa: USDActualizado: mar., 4 de mar
Divisa: USDActualizado: mar., 4 de mar
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Estadísticas de accionistas
Actualizado: sáb., 31 de ene
Actualizado: sáb., 31 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
14.63%
Capital World Investors
11.09%
The Vanguard Group, Inc.
10.13%
T. Rowe Price Investment Management, Inc.
8.12%
BlackRock Institutional Trust Company, N.A.
5.22%
Otro
50.82%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
14.63%
Capital World Investors
11.09%
The Vanguard Group, Inc.
10.13%
T. Rowe Price Investment Management, Inc.
8.12%
BlackRock Institutional Trust Company, N.A.
5.22%
Otro
50.82%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
71.06%
Investment Advisor/Hedge Fund
19.64%
Hedge Fund
13.85%
Research Firm
2.62%
Pension Fund
0.98%
Individual Investor
0.89%
Bank and Trust
0.79%
Sovereign Wealth Fund
0.28%
Family Office
0.02%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
879
176.98M
109.27%
-8.42M
2025Q3
815
172.95M
106.78%
-7.24M
2025Q2
801
185.40M
116.34%
+8.33M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
2023Q3
763
145.13M
101.24%
-1.40M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
23.69M
14.63%
+46.05K
+0.19%
Sep 30, 2025
Capital World Investors
17.96M
11.09%
+5.24M
+41.17%
Dec 31, 2025
The Vanguard Group, Inc.
16.44M
10.15%
-235.68K
-1.41%
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
13.16M
8.12%
-2.89M
-18.02%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
8.45M
5.22%
-272.23K
-3.12%
Sep 30, 2025
Wellington Management Company, LLP
6.59M
4.07%
+243.03K
+3.83%
Sep 30, 2025
Bellevue Asset Management AG
6.24M
3.86%
-1.61M
-20.49%
Sep 30, 2025
State Street Investment Management (US)
4.39M
2.71%
-141.75K
-3.13%
Sep 30, 2025
Deep Track Capital LP
3.81M
2.35%
-1.08M
-22.15%
Sep 30, 2025
Two Sigma Investments, LP
3.65M
2.25%
-806.92K
-18.11%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Invesco Biotechnology & Genome ETF
5.24%
ARK Genomic Revolution ETF
4.11%
Virtus LifeSci Biotech Products ETF
3.34%
Franklin Genomic Advancements ETF
2.69%
Invesco Dorsey Wright Healthcare Momentum ETF
2.57%
First Trust Health Care Alphadex Fund
2.47%
VanEck Morningstar SMID Moat ETF
2.38%
WisdomTree BioRevolution Fund
2.28%
State Street SPDR S&P Biotech ETF
2.28%
Capital Group US Small and Mid Cap ETF
2.04%
Ver más
Invesco Biotechnology & Genome ETF
Proporción5.24%
ARK Genomic Revolution ETF
Proporción4.11%
Virtus LifeSci Biotech Products ETF
Proporción3.34%
Franklin Genomic Advancements ETF
Proporción2.69%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción2.57%
First Trust Health Care Alphadex Fund
Proporción2.47%
VanEck Morningstar SMID Moat ETF
Proporción2.38%
WisdomTree BioRevolution Fund
Proporción2.28%
State Street SPDR S&P Biotech ETF
Proporción2.28%
Capital Group US Small and Mid Cap ETF
Proporción2.04%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
